-
公开(公告)号：EP3646885A1
公开(公告)日：2020-05-06
申请号：EP18825437.9
申请日：2018-06-29
发明人： TAKAHATA, Masahiko , SATO, Dai , OTA, Masahiro , SHIMIZU, Tomohiro , FUKUDA, Chie , TSUDA, Eisuke
IPC分类号： A61K39/395 , A61P19/10 , C07K16/18 , C07K16/46
摘要： An object of the present invention is to provide a pharmaceutical agent for the treatment and/or prophylaxis of pediatric osteoporosis without causing bone growth disorder in a subject to be medicated. A pharmaceutical composition for the treatment and/or prophylaxis of pediatric osteoporosis contains an antibody or a functional fragment thereof which binds to Siglec-15 and has activity of suppressing formation of osteoclasts and/or bone resorption by osteoclasts.
-
公开(公告)号：EP3699277A1
公开(公告)日：2020-08-26
申请号：EP20165057.9
申请日：2010-04-07
IPC分类号： C12N15/09 , A61K39/395 , A61P1/02 , A61P3/14 , A61P19/08 , A61P19/10 , A61P35/00 , A61P35/04 , C07K16/18 , C07K16/46 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12P21/08 , A61K39/00 , A61P19/02 , C07K16/28
摘要： Provided is a pharmaceutical composition for treating and/or preventing abnormal bone metabolism targeting a protein encoded by a gene strongly expressed in osteoclasts. Specifically provided is a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation, and the like.
-
公开(公告)号：EP2625205A2
公开(公告)日：2013-08-14
申请号：EP11778519.6
申请日：2011-10-04
发明人： WATANABE, Ichiro , HIRUMA, Yoshiharu , TSUDA, Eisuke , MATSUOKA, Tatsuji , OHTSUKA, Toshiaki , TAKAHASHI, Tohru , AGATSUMA, Toshinori , MILLER, Sandra , MÜHLBACHER, Robert , BAEHS, Kathrin-Ladetzki , RUNZ, Steffen , SCHUBERT, Ulrike , SCHUSTER, Ingrid , PONSEL, Dirk
IPC分类号： C07K16/28
CPC分类号： A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/2803 , C07K2317/21 , C07K2317/55 , C07K2317/92
摘要： An isolated antibody capable of binding Siglec-15 which inhibits osteoclast formation and/or osteoclastic bone resorption, or a functional fragment thereof. The heavy chain of the antibody comprises a CDRH1 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 106, a CDRH2 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 107, and a CDRH3 comprising a sequence having at least 80% sequence identity to one of SEQ ID NOS: 35, 45, 55, 65 or 80. The light chain of the antibody comprises a CDRL1 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 73 or 83, a CDRL2 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 108, and a CDRL3 comprising a sequence having at least 80% sequence identity to one of SEQ ID NOS: 40, 50, 60, 70, 90, 100 or 109.
-
公开(公告)号：EP2377932B1
公开(公告)日：2020-11-18
申请号：EP10761710.2
申请日：2010-04-07
-
公开(公告)号：EP2377932A1
公开(公告)日：2011-10-19
申请号：EP10761710.2
申请日：2010-04-07
IPC分类号： C12N15/09 , A61K39/395 , A61P1/02 , A61P3/14 , A61P19/08 , A61P19/10 , A61P35/00 , A61P35/04 , C07K16/18 , C07K16/46 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12P21/08
摘要： Provided is a pharmaceutical composition for treating and/or preventing abnormal bone metabolism targeting a protein encoded by a gene strongly expressed in osteoclasts. Specifically provided is a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation, and the like.
摘要翻译： 本发明提供用于治疗和/或预防异常骨代谢靶向由破骨细胞强烈表达的基因编码的蛋白质的药物组合物。 具体提供含有特异性识别人Siglec-15并具有抑制破骨细胞形成活性的抗体的药物组合物等。
-
-
-
-
搜索结果
5 条记录 (耗时 0.022 秒)
